--12-31Q30000818033falseHERON THERAPEUTICS, INC. /DE/http://fasb.org/us-gaap/2025#UsefulLifeTermOfLeaseMemberhttp://www.herontx.com/20250930#CompanyChiefExecutiveOfficerMemberhttp://fasb.org/us-gaap/2025#AccountingStandardsUpdate202404Member0000818033hrtx:SUSTOLMember2025-09-300000818033hrtx:NotesPayableMember2025-01-012025-09-300000818033hrtx:CINVANTIMember2024-12-310000818033hrtx:TrancheOneCMemberhrtx:HerculesCapitalIncMember2023-08-150000818033us-gaap:RetainedEarningsMember2024-09-300000818033us-gaap:RetainedEarningsMember2023-12-310000818033us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2025-07-012025-09-300000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2024-07-012024-09-300000818033us-gaap:CommonStockMember2024-03-310000818033hrtx:TrancheOneBMemberhrtx:HerculesCapitalIncMember2023-08-150000818033hrtx:HerculesCapitalIncMember2025-01-012025-09-300000818033us-gaap:RetainedEarningsMember2024-12-310000818033hrtx:HerculesCapitalIncMembersrt:MaximumMember2025-08-082025-08-080000818033us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033us-gaap:EmployeeStockOptionMember2025-01-012025-09-300000818033us-gaap:RetainedEarningsMember2024-06-3000008180332025-10-300000818033hrtx:HerculesCapitalIncMember2025-09-300000818033hrtx:ZYNRELEFMember2025-09-300000818033hrtx:HerculesCapitalIncMember2023-08-0900008180332024-06-300000818033hrtx:HerculesCapitalIncMember2024-07-012024-09-3000008180332024-01-012024-12-310000818033us-gaap:RetainedEarningsMember2025-04-012025-06-300000818033stpr:NC2025-08-3100008180332024-12-310000818033us-gaap:CommonStockMember2024-12-310000818033hrtx:SeriesAConvertiblePreferredStockMemberus-gaap:PrivatePlacementMember2025-08-080000818033us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-09-300000818033us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000818033us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-09-300000818033us-gaap:FairValueInputsLevel2Memberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033us-gaap:SellingAndMarketingExpenseMember2025-01-012025-09-300000818033us-gaap:AdditionalPaidInCapitalMember2024-03-310000818033us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2025-08-080000818033us-gaap:CommonStockMemberhrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2025-07-012025-09-300000818033us-gaap:CommonStockMember2024-06-300000818033us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033us-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033hrtx:HerculesCapitalIncMember2025-08-080000818033us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-09-300000818033us-gaap:SalesRevenueNetMemberhrtx:LargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300000818033us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300000818033hrtx:ZYNRELEFMember2024-07-012024-09-300000818033us-gaap:CommonStockMemberhrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2025-08-0800008180332024-01-012024-09-300000818033us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033hrtx:HerculesCapitalIncMemberhrtx:TrancheOneMember2025-08-0800008180332023-08-150000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2021-05-310000818033us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-09-300000818033us-gaap:CommonStockMember2024-04-012024-06-300000818033us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300000818033us-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033us-gaap:CommonStockMember2024-01-012024-03-310000818033us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-09-300000818033us-gaap:PrivatePlacementMemberus-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-3000008180332025-03-310000818033us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300000818033hrtx:ForeignCommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-09-300000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2025-08-080000818033hrtx:AponvieMember2025-09-300000818033us-gaap:DomesticCorporateDebtSecuritiesMember2025-09-300000818033us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-09-300000818033hrtx:SUSTOLMember2024-01-012024-09-300000818033hrtx:HerculesCapitalIncMember2025-08-1200008180332025-09-300000818033us-gaap:SeriesAPreferredStockMember2025-01-012025-09-300000818033us-gaap:RetainedEarningsMember2025-06-300000818033hrtx:TwoThousandThirtyOneSeniorUnsecuredConvertibleNotesMemberhrtx:RubricCapitalManagementLPMember2025-07-012025-09-300000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2021-05-012021-05-310000818033hrtx:CINVANTIMember2025-09-300000818033us-gaap:ConvertibleDebtSecuritiesMember2024-01-012024-09-300000818033us-gaap:RetainedEarningsMember2025-09-300000818033us-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2025-07-012025-09-300000818033us-gaap:RetainedEarningsMember2025-03-310000818033hrtx:SUSTOLMember2025-01-012025-09-300000818033us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033hrtx:SubleaseAgreementMember2021-10-310000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310000818033us-gaap:AdditionalPaidInCapitalMember2025-06-300000818033hrtx:ForeignCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033hrtx:EmployeeStockPurchasePlanMember2025-01-012025-09-300000818033us-gaap:ResearchAndDevelopmentExpenseMember2025-07-012025-09-300000818033hrtx:AllowanceForSalesReturns1Member2025-09-3000008180332024-01-012024-03-310000818033hrtx:ForeignCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2025-09-3000008180332024-09-300000818033hrtx:TwoThousandThirtyOneSeniorUnsecuredConvertibleNotesMemberhrtx:RubricCapitalManagementLPMember2025-01-012025-09-300000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000818033us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2025-07-012025-09-300000818033us-gaap:CommonStockMember2025-09-300000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000818033hrtx:LargestCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300000818033us-gaap:RestrictedStockUnitsRSUMember2025-09-300000818033us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhrtx:ThirdLargestCustomerMember2025-07-012025-09-3000008180332023-12-310000818033us-gaap:CommonStockMember2025-01-012025-03-310000818033us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberhrtx:SecondLargestCustomerMember2025-01-012025-09-300000818033hrtx:AponvieMember2024-12-3100008180332025-01-012025-09-300000818033us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhrtx:ThirdLargestCustomerMember2025-01-012025-09-300000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMemberus-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300000818033us-gaap:CommonStockMember2023-12-310000818033us-gaap:SellingAndMarketingExpenseMember2025-07-012025-09-300000818033hrtx:TwoThousandThirtyOneSeniorUnsecuredConvertibleNotesMemberhrtx:RubricCapitalManagementLPMember2025-08-082025-08-0800008180332024-07-012024-09-300000818033us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberhrtx:ThirdLargestCustomerMember2025-01-012025-09-300000818033us-gaap:CommonStockMember2025-07-012025-09-300000818033us-gaap:WarrantMemberhrtx:TrancheOneAMember2023-08-092023-08-090000818033us-gaap:RetainedEarningsMember2024-01-012024-03-310000818033hrtx:ForeignCommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033hrtx:SUSTOLMember2024-12-310000818033us-gaap:PrivatePlacementMember2025-07-012025-09-300000818033hrtx:ZYNRELEFMember2024-12-310000818033us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033hrtx:AponvieMember2024-07-012024-09-300000818033us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000818033hrtx:HerculesCapitalIncMemberhrtx:TrancheThreeMember2025-08-080000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000818033us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000818033stpr:CA2025-07-012025-09-300000818033hrtx:AllowanceForDistributorFeesMember2025-01-012025-09-300000818033us-gaap:PrivatePlacementMember2025-08-082025-08-080000818033us-gaap:RetainedEarningsMember2025-07-012025-09-300000818033us-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-09-300000818033hrtx:AllowanceForRebatesAndChargebacksMember2024-12-310000818033us-gaap:CommonStockMemberhrtx:TwoThousandThirtyOneSeniorUnsecuredConvertibleNotesMemberhrtx:RubricCapitalManagementLPMember2025-08-080000818033hrtx:AponvieMember2025-07-012025-09-300000818033us-gaap:CommonStockMember2025-06-300000818033hrtx:HerculesCapitalIncMember2024-01-012024-09-300000818033hrtx:HerculesCapitalIncMemberhrtx:TrancheOneMember2025-08-120000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300000818033hrtx:EmployeeStockPurchasePlanMember2024-01-012024-09-300000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2025-01-012025-09-300000818033hrtx:AllowanceForDistributorFeesMember2025-09-300000818033hrtx:CINVANTIMember2024-01-012024-09-300000818033us-gaap:FairValueMeasurementsRecurringMember2025-09-300000818033us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhrtx:SecondLargestCustomerMember2025-01-012025-09-300000818033us-gaap:CommonStockMemberhrtx:ExchangeAgreementMember2025-08-082025-08-080000818033us-gaap:AdditionalPaidInCapitalMember2025-03-310000818033stpr:CA2024-01-012024-09-300000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2025-01-012025-09-300000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000818033hrtx:ZYNRELEFMember2025-07-012025-09-300000818033us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300000818033us-gaap:RetainedEarningsMember2024-04-012024-06-300000818033us-gaap:CommonStockMember2025-04-012025-06-300000818033hrtx:TrancheTwoMemberhrtx:HerculesCapitalIncMember2025-08-080000818033us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300000818033hrtx:SeriesAConvertiblePreferredStockMembersrt:MinimumMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2025-10-132025-10-130000818033us-gaap:EmployeeStockOptionMembersrt:MaximumMember2025-01-012025-09-300000818033us-gaap:FairValueMeasurementsRecurringMemberhrtx:UnitedStatesCommercialPaperMember2025-09-3000008180332024-04-012024-06-300000818033us-gaap:RetainedEarningsMember2025-01-012025-03-310000818033us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhrtx:SecondLargestCustomerMember2025-07-012025-09-300000818033hrtx:AllowanceForRebatesAndChargebacksMember2025-09-300000818033hrtx:ForeignCommercialPaperMember2025-09-300000818033hrtx:SUSTOLMember2025-07-012025-09-300000818033us-gaap:USTreasurySecuritiesMember2025-09-300000818033us-gaap:CommonStockMember2025-03-310000818033us-gaap:DomesticCorporateDebtSecuritiesMember2024-12-310000818033stpr:CA2024-07-012024-09-300000818033us-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000818033us-gaap:ForeignCorporateDebtSecuritiesMember2024-12-310000818033hrtx:HerculesCapitalIncMember2025-08-122025-08-120000818033us-gaap:GeneralAndAdministrativeExpenseMember2025-07-012025-09-300000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2025-09-300000818033hrtx:HerculesCapitalIncMember2023-08-1500008180332025-04-012025-06-300000818033us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300000818033us-gaap:EmployeeStockOptionMembersrt:MinimumMember2025-01-012025-09-300000818033hrtx:CINVANTIMember2024-07-012024-09-300000818033us-gaap:SalesRevenueNetMemberhrtx:LargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-3000008180332025-06-300000818033hrtx:ForeignCommercialPaperMember2024-12-310000818033us-gaap:AdditionalPaidInCapitalMember2023-12-310000818033hrtx:TwoThousandThirtyOneSeniorUnsecuredConvertibleNotesMember2025-01-012025-09-300000818033us-gaap:RetainedEarningsMember2024-03-310000818033us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000818033hrtx:AllowanceForSalesReturns1Member2024-12-3100008180332025-01-012025-03-310000818033hrtx:HerculesCapitalIncMember2025-07-012025-09-300000818033us-gaap:WarrantMember2024-01-012024-09-300000818033us-gaap:OtherNoncurrentLiabilitiesMember2025-09-300000818033hrtx:CINVANTIMember2025-01-012025-09-300000818033us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300000818033hrtx:TwoThousandThirtyOneSeniorUnsecuredConvertibleNotesMemberhrtx:RubricCapitalManagementLPMember2025-08-080000818033hrtx:CINVANTIMember2025-07-012025-09-300000818033us-gaap:AdditionalPaidInCapitalMember2024-06-3000008180332023-08-092023-08-090000818033us-gaap:AdditionalPaidInCapitalMember2024-12-310000818033hrtx:AponvieMember2024-01-012024-09-300000818033hrtx:HerculesCapitalIncMember2025-02-132025-02-130000818033hrtx:SignificantCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300000818033hrtx:HerculesCapitalIncMember2025-08-082025-08-080000818033us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-09-300000818033hrtx:HerculesCapitalIncMemberhrtx:TrancheOneAMember2023-08-150000818033stpr:NC2025-08-012025-08-310000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000818033hrtx:AllowanceForDistributorFeesMember2024-12-310000818033us-gaap:CommonStockMemberhrtx:HerculesCapitalIncMembersrt:MaximumMember2023-08-090000818033us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2025-09-300000818033us-gaap:CashAndCashEquivalentsMember2025-09-300000818033us-gaap:RetainedEarningsMember2024-07-012024-09-300000818033hrtx:UnitedStatesCommercialPaperMember2025-09-300000818033hrtx:SignificantCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300000818033us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300000818033us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000818033hrtx:TwoThousandThirtyOneSeniorUnsecuredConvertibleNotesMemberhrtx:RubricCapitalManagementLPMember2025-09-300000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2025-08-082025-08-080000818033us-gaap:CommonStockMember2024-09-300000818033us-gaap:FairValueInputsLevel2Memberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-09-300000818033srt:MinimumMemberhrtx:TwoThousandThirtyOneSeniorUnsecuredConvertibleNotesMemberhrtx:RubricCapitalManagementLPMember2025-08-082025-08-080000818033hrtx:SUSTOLMember2024-07-012024-09-300000818033us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300000818033us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-09-300000818033hrtx:ZYNRELEFMember2025-01-012025-09-300000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2024-01-012024-09-300000818033us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000818033us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310000818033hrtx:AponvieMember2025-01-012025-09-3000008180332023-08-152023-08-150000818033us-gaap:PrivatePlacementMember2025-08-080000818033hrtx:AllowanceForRebatesAndChargebacksMember2025-01-012025-09-300000818033hrtx:ZYNRELEFMember2024-01-012024-09-300000818033hrtx:AllowanceForSalesReturns1Member2025-01-012025-09-300000818033us-gaap:WarrantMember2025-01-012025-09-3000008180332025-07-012025-09-300000818033us-gaap:CommonStockMember2024-07-012024-09-300000818033hrtx:SignificantCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300000818033stpr:CA2025-09-300000818033us-gaap:EmployeeStockOptionMember2025-01-012025-09-300000818033us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2025-08-082025-08-080000818033us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-09-300000818033hrtx:SeriesAConvertiblePreferredStockMemberus-gaap:PrivatePlacementMember2025-08-082025-08-080000818033us-gaap:USTreasurySecuritiesMember2024-12-310000818033us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberhrtx:UnitedStatesCommercialPaperMember2025-09-300000818033us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000818033us-gaap:AdditionalPaidInCapitalMember2024-09-300000818033hrtx:TwoThousandTwentySixSeniorUnsecuredConvertibleNotesMember2025-07-012025-09-300000818033us-gaap:AdditionalPaidInCapitalMember2025-09-300000818033us-gaap:RestrictedStockUnitsRSUMember2024-12-310000818033us-gaap:ConvertibleDebtSecuritiesMember2025-01-012025-09-300000818033us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000818033stpr:CA2025-01-012025-09-3000008180332024-03-310000818033us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-09-30xbrli:pureutr:sqftxbrli:shareshrtx:Segmentiso4217:USDxbrli:sharesiso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


☒		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025


☐		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _ to _

Commission file number: 001-33221

HERON THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)


Delaware (State or other jurisdiction of incorporation or organization)	94-2875566 (I.R.S. Employer Identification No.)

100 Regency Forest Drive, Suite 300 Cary, North Carolina	27518
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (858) 251-4400

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	HRTX	The Nasdaq Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☑

Non-accelerated filer	☐	Smaller reporting company	☐

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

The number of shares of the registrant's common stock, par value $0.01 per share, outstanding as of October 30, 2025 was 183,362,522.

HERON THERAPEUTICS, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025

TABLE OF CONTENTS


PART I.	FINANCIAL INFORMATION

ITEM 1.	Condensed Consolidated Financial Statements

	Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024	5

	Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited)	6

	Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited)	7

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited)	9

	Notes to Condensed Consolidated Financial Statements (Unaudited)	10

ITEM 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	24

ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	32

ITEM 4.	Controls and Procedures	32

PART II.	OTHER INFORMATION

ITEM 1.	Legal Proceedings	33

ITEM 1A.	Risk Factors	35

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37

ITEM 3.	Defaults upon Senior Securities	37

ITEM 4.	Mine Safety Disclosures	37

ITEM 5.	Other Information	37

ITEM 6.	Exhibits	38

	SIGNATURES	40

In this Quarterly Report on Form 10-Q, all references to "Heron," the "Company," "we," "us," "our" and similar terms refer to Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics B.V. Heron Therapeutics®, the Heron logo, ZYNRELEF®, APONVIE®, CINVANTI®, SUSTOL®, and Biochronomer® are our trademarks, which are protected under applicable intellectual property laws and are the property of Heron. All other trademarks appearing or incorporated by reference into this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks referred to in this Quarterly Report on Form 10-Q may appear without the ®, ™ or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks. We do not intend our use or display of other parties' trademarks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify forward-looking statements by the use of the words "anticipate," "assume," "believe," "could," "estimate," "expect," "intend," "may," "might," "project," "should," "will," "would," and other expressions that predict or indicate future events and trends and which do not relate to historical matters. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business and commercialization strategy, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, addressable patient population, research and development expenses, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from our anticipated future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking statements include, but are not limited to, statements including:

•

our ability to successfully commercialize, market and achieve market acceptance of ZYNRELEF® (bupivacaine and meloxicam) extended-release solution ("ZYNRELEF"), APONVIE® (aprepitant) injectable emulsion ("APONVIE"), CINVANTI® (aprepitant) injectable emulsion ("CINVANTI"), and SUSTOL® (granisetron) extended-release injection ("SUSTOL" and together with ZYNRELEF, APONVIE and CINVANTI, our "Products") in the United States ("U.S."), and our positioning relative to products that now or in the future compete with our Products or product candidates;

•

our estimates regarding the potential market opportunities for our Products and our product candidates, if approved, and our ability to capture the potential additional market opportunity from the expanded ZYNRELEF label approved in the U.S.;

•

our ability to establish and maintain successful commercial arrangements, including our co-promotion agreement with CrossLink Network, LLC ("CrossLink Network");

•

the realization of anticipated benefits from our co-promotion agreement with CrossLink Network;

•

the timing and outcome of our pending patent litigations;

•

whether we are required to write-off any additional inventory in the future;

•

our ability to establish satisfactory pricing and obtain adequate reimbursement from government and third-party payors of our Products and product candidates that receive regulatory approvals;

•

whether clinical trials of our Products and product candidates are indicative of the results in future clinical trials;

•

our ability to successfully launch our ZYNRELEF Vial Access Needle ("VAN") in the U.S.;

•

our ability to develop, acquire and advance product candidates into, and successfully complete, clinical trials, and our ability to submit for and obtain regulatory approval for product candidates in our anticipated timing, or at all;

•

the clinical utility of our Products and product candidates and their potential advantages compared to other treatments;

•

our competitors’ activities, including decisions as to the timing of competing product launches, generic entrants, pricing and discounting;

•

the safety and efficacy results of our clinical trials and other required studies for expansion of the indications for our Products and approval of our product candidates and the data to support such clinical trials, potential regulatory approval or further development of any of our Products or product candidates;

•

our ability to meet the postmarketing study requirements within the mandated timelines of the U.S. Food and Drug Administration ("FDA") and to obtain favorable results and comply with standard postmarketing requirements, including U.S. federal advertising and promotion laws, federal and state anti-fraud and abuse laws, healthcare information privacy

and security laws, safety information, safety surveillance and disclosure of payments or other transfers of value to healthcare professionals and entities for Products or any of our product candidates;

•

our ability to successfully develop and achieve regulatory approval for any product candidates utilizing our proprietary Biochronomer® drug delivery technology ("Biochronomer Technology");

•

our ability to establish key collaborations and vendor relationships for our Products and our product candidates;

•

our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire;

•

our ability to establish and maintain arrangements for the manufacture of our Products and product candidates and the ability and sufficiency of our current manufacturing third-party partners to produce clinical and commercial quantities of our Products and product candidates without delays, supply constraints or changes in the regulatory or geopolitical environment;

•

the failure to renew, or the revocation of, any license or other required permits;

•

our ability to successfully operate in non-U.S. jurisdictions in which we may choose to do business, including compliance with applicable regulatory requirements and laws;

•

our ability to obtain and enforce intellectual property rights to protect our Products, our product candidates, our Biochronomer Technology and our other technology;

•

our ability to successfully defend ourselves against pending or threatened litigation or investigations, including unforeseen third-party infringement claims involving our Products and product candidates;

•

our inability or delay in achieving or sustaining profitability;

•

the impacts of global economic and political developments on our business and the financial market, including the impact of geopolitical conflicts and acts of war, terrorism and civil disorder, global pandemics and other public health emergencies, tariffs and other trade protection measures, changes to interest rates and inflationary pressure, natural and man-made disasters, and other sources of volatility, which could result in economic slowdowns or recessions and market disruptions and adversely affect our financial condition, results of operations and cash flows;

•

the impact of evolving legal and regulatory requirements and interpretations thereof, including legislative or executive actions, policy changes in governmental agencies and judicial decisions overturning or establishing new precedents;

•

changes in the industry we operate;

•

our ability to retain, attract and hire key personnel;

•

our estimates regarding our capital requirements;

•

our ability to obtain additional financing and raise capital as necessary to fund operations or pursue business opportunities;

•

the cost and availability of capital and any restrictions imposed by lenders or creditors; and

•

the volatility and unpredictability of the stock market, credit market conditions and impact on the value of our common stock and our ability to access capital markets.

You should refer to the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 27, 2025, (the "2024 Annual Report"), Quarterly reports on Form 10-Q and other reports for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements were based on information, plans and estimates as of the date of this Quarterly Report on Form 10-Q, and while we may elect to update these forward-looking statements in our future filings under the Exchange Act, we assume no obligation to update any forward-looking statements to reflect changes in underlying assumptions or

factors, new information, future events or other changes, except as required by law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

HERON THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets

(In thousands)


	September 30, 2025			December 31, 2024
	(Unaudited)			(See Note 2)
ASSETS
Current assets:
Cash and cash equivalents	$	43,068		$	25,802
Short-term investments		12,419			33,481
Accounts receivable, net		81,047			78,881
Inventory, net		70,025			53,160
Prepaid expenses and other current assets		22,841			17,690
Total current assets		229,400			209,014
Property and equipment, net		12,960			14,863
Right-of-use lease assets		708			2,787
Other assets		5,882			6,483
Total assets	$	248,950		$	233,147
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	12,017		$	11,709
Accrued clinical and manufacturing liabilities		19,663			25,402
Accrued payroll and employee liabilities		8,748			9,554
Other accrued liabilities		48,500			41,755
Current lease liabilities		780			3,037
Total current liabilities		89,708			91,457
Non-current notes payable, net		107,487			25,026
Non-current convertible notes payable, net		32,176			149,700
Other non-current liabilities		4,694			615
Total liabilities		234,065			266,798
Stockholders' equity (deficit):
Common stock		1,833			1,521
Series A convertible preferred stock		7,862			—
Additional paid-in capital		1,942,025			1,884,409
Accumulated other comprehensive loss		—			13
Accumulated deficit		(1,936,835	)		(1,919,594	)
Total stockholders' equity (deficit)		14,885			(33,651	)
Total liabilities and stockholders' equity (deficit)	$	248,950		$	233,147

See accompanying notes.

HERON THERAPEUTICS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except per share amounts)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Revenues:
Net product sales	$	38,213		$	32,810		$	114,316		$	103,504
Cost of product sales		11,914			9,458			30,228			28,420
Gross profit		26,299			23,352			84,088			75,084
Operating expenses:
Research and development		3,470			4,465			8,683			13,505
General and administrative		13,980			12,373			41,153			41,252
Sales and marketing		12,942			10,972			36,828			36,028
Total operating expenses		30,392			27,810			86,664			90,785
Loss from operations		(4,093	)		(4,458	)		(2,576	)		(15,701	)
Loss on debt extinguishment		(11,339	)		—			(11,339	)		—
Other expense, net		(2,063	)		(390	)		(3,326	)		(1,542	)
Net loss		(17,495	)		(4,848	)		(17,241	)		(17,243	)
Other comprehensive loss:
Unrealized gain (loss) on short-term investments		1			48			(13	)		27
Comprehensive loss	$	(17,494	)	$	(4,800	)	$	(17,254	)	$	(17,216	)
Basic and diluted net loss per share	$	(0.10	)	$	(0.03	)	$	(0.11	)	$	(0.11	)
Weighted average common shares outstanding, basic and diluted		170,348			152,830			159,524			152,213

See accompanying notes.

HERON THERAPEUTICS, INC.

Condensed Consolidated Statements of Stockholders' Equity (Deficit)

(Unaudited)

(In thousands)


	Common Stock				Series A Preferred Stock
	Shares		Amount		Shares		Amount		Additional Paid-In Capital			Accumulated Other Comprehensive (Loss) Income			Accumulated Deficit			Total Stockholders' Equity (Deficit)
Balance as of December 31, 2024		152,128	$	1,521		—	$	—	$	1,884,409		$	13		$	(1,919,594	)	$	(33,651	)
Issuance of common stock under equity incentive plan		299		3		—		—		61			—			—			64
Stock-based compensation expense		—		—		—		—		2,511			—			—			2,511
Net income		—		—		—		—		—			—			2,635			2,635
Net unrealized loss on short-term investments		—		—		—		—		—			(12	)		—			(12	)
Comprehensive income																			2,623
Balance as of March 31, 2025 (unaudited)		152,427		1,524		—		—		1,886,981			1			(1,916,959	)		(28,453	)
Issuance of common stock under equity incentive plan		438		5		—		—		189			—			—			194
Issuance of common stock under the employee stock purchase plan		388		4		—		—		583			—			—			587
Stock-based compensation expense		—		—		—		—		2,797			—			—			2,797
Net loss		—		—		—		—		—			—			(2,381	)		(2,381	)
Net unrealized loss on short-term investments		—		—		—		—		—			(2	)		—			(2	)
Comprehensive loss																			(2,383	)
Balance as of June 30, 2025 (unaudited)		153,253		1,533		—		—		1,890,550			(1	)		(1,919,340	)		(27,258	)
Issuance of common stock under equity incentive plan		179		1		—		—		(52	)		—			—			(51	)
Issuance of common stock in settlement of 2026 Convertible Notes		16,667		167		—		—		30,500			—			—			30,667
Issuance of common stock in a private placement equity offering		13,225		132		—		—		18,175			—			—			18,307
Issuance of Series A convertible preferred stock in a private placement equity offering		—		—		524		7,862		—			—			—			7,862
Stock-based compensation expense		—		—		—		—		2,852			—			—			2,852
Net loss		—		—		—		—		—			—			(17,495	)		(17,495	)
Net unrealized gain on short-term investments		—		—		—		—		—			1			—			1
Comprehensive loss																			(17,494	)
Balance as of September 30, 2025 (unaudited)		183,324	$	1,833		524	$	7,862	$	1,942,025		$	-		$	(1,936,835	)	$	14,885


	Common Stock				Series A Preferred Stock
	Shares		Amount		Shares		Amount		Additional Paid-In Capital		Accumulated Other Comprehensive (Loss) Income			Accumulated Deficit			Total Stockholders' (Deficit)
Balance as of December 31, 2023		150,285	$	1,503		—	$	—	$	1,870,525	$	13		$	(1,906,014	)	$	(33,973	)
Issuance of common stock under equity incentive plan		93		1		—		—		10		—			—			11
Stock-based compensation expense		—		—		—		—		3,375		—			—			3,375
Net loss		—		—		—		—		—		—			(3,160	)		(3,160	)
Net unrealized loss on short-term investments		—		—		—		—		—		(19	)		—			(19	)
Comprehensive loss																		(3,179	)
Balance as of March 31, 2024 (unaudited)		150,378		1,504		—		—		1,873,910		(6	)		(1,909,174	)		(33,766	)
Issuance of common stock under equity incentive plan		872		9		—		—		309		—			—			318
Issuance of common stock under the employee stock purchase plan		328		3		—		—		172		—			—			175
Stock-based compensation expense		—		—		—		—		4,570		—			—			4,570
Net loss		—		—		—		—		—		—			(9,235	)		(9,235	)
Net unrealized loss on short-term investments		—		—		—		—		—		(2	)		—			(2	)
Comprehensive loss																		(9,237	)
Balance as of June 30, 2024 (unaudited)		151,578		1,516		—		—		1,878,961		(8	)		(1,918,409	)		(37,940	)
Issuance of common stock under equity incentive plan		124		1		—		—		12		—			—			13
Stock-based compensation expense		—		—		—		—		2,722		—			—			2,722
Net loss		—		—		—		—		—		—			(4,848	)		(4,848	)
Net unrealized gain on short-term investments		—		—		—		—		—		48			—			48
Comprehensive loss																		(4,800	)
Balance as of September 30, 2024 (unaudited)		151,702	$	1,517		—	$	—	$	1,881,695	$	40		$	(1,923,257	)	$	(40,005	)

See accompanying notes.

HERON THERAPEUTICS, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)


	Nine Months Ended September 30,
	2025			2024
Operating activities:
Net loss	$	(17,241	)	$	(17,243	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		8,160			10,667
Depreciation and amortization		1,777			1,911
Amortization of debt discount		505			504
Amortization of debt issuance costs		108			157
Accretion of discount on short-term investments		(650	)		(1,754	)
Retirement and impairment of property and equipment		409			4,269
Loss on extinguishment of debt		11,339			—
Change in operating assets and liabilities:
Accounts receivable		(2,166	)		(6,902	)
Inventory		(16,865	)		(3,840	)
Prepaid expenses and other assets		(4,550	)		(3,769	)
Accounts payable		308			6,948
Accrued clinical and manufacturing liabilities		(5,787	)		208
Accrued payroll and employee related liabilities		(806	)		(693	)
Other accrued expenses		7,052			(1,212	)
Net cash used in operating activities		(18,407	)		(10,749	)
Investing activities:
Purchases of short-term investments		(38,214	)		(90,745	)
Maturities and sales of short-term investments		59,914			99,109
Purchases of property and equipment		(317	)		(1,068	)
Proceeds from sale of property and equipment		82			—
Net cash provided by investing activities		21,465			7,296
Financing activities:
Proceeds from the sale of common stock		19,838			—
Cash paid for issuance costs of stock		(1,531	)		—
Proceeds from sale of Series A convertible preferred stock		7,862			—
Cash paid for 2026 Convertible Notes extinguishment		(125,000	)		—
Cash paid for notes payable extinguishment		(25,000	)		—
Proceeds from 2031 Convertible Notes issuance		33,250			—
Cash paid for 2031 Convertible Notes debt issuance costs		(1,386	)		—
Proceeds from notes payable issuance		108,787			—
Cash paid for notes payable debt issuance cost		(3,406	)		—
Proceeds from purchases under the employee stock purchase plan		587			175
Receipts for stock issued under the equity incentive plan		207			342
Net cash provided by financing activities		14,208			517
Net increase (decrease) in cash and cash equivalents		17,266			(2,936	)
Cash and cash equivalents at beginning of period		25,802			28,677
Cash and cash equivalents at end of period	$	43,068		$	25,741
Supplemental disclosure of cash flow information:
Interest paid	$	3,862		$	3,088

See accompanying notes.

HERON THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Business

We are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.

ZYNRELEF® (bupivacaine and meloxicam) extended-release solution ("ZYNRELEF") is approved in the United States ("U.S.") for the management of postoperative pain. APONVIE® (aprepitant) injectable emulsion ("APONVIE") is approved in the U.S. for the prevention of postoperative nausea and vomiting. CINVANTI® (aprepitant) injectable emulsion ("CINVANTI") and SUSTOL® (granisetron) extended-release injection ("SUSTOL") are both approved in the U.S. for the prevention of chemotherapy-induced nausea and vomiting.

As of September 30, 2025, we had cash, cash equivalents and short-term investments of $55.5 million. Based on our current operating plan and projections, management believes that the Company's cash, cash equivalents and short-term investments will be sufficient to meet the Company's anticipated cash requirements for a period of at least one year from the issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. We have based this estimate on assumptions that may prove wrong, and we could utilize our available capital resources sooner than we currently expect, which would have a material impact on our operations.

2. Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and the requirements of the SEC for interim reporting. Accordingly, since they are interim statements, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2025, are not necessarily indicative of the results that may be expected for other quarters or the year ending December 31, 2025. The condensed consolidated balance sheet as of December 31, 2024, has been derived from the audited consolidated financial statements as of that date. For more complete financial information, these condensed consolidated financial statements and the related notes thereto should be read in conjunction with the audited consolidated financial statements included in our 2024 Annual Report.

3. Accounting Policies

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics B.V., which was organized in the Netherlands in March 2015. Heron Therapeutics B.V. has no operations and no material assets or liabilities, and there have been no significant transactions related to Heron Therapeutics B.V. since its inception.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our significant accounting policies that involve significant judgment and estimates include revenue recognition, investments, inventory and the related reserves, accrued clinical and manufacturing liabilities, income taxes, stock-based compensation and accounting for debt and equity transactions. Actual results could differ materially from those estimates.

Cash, Cash Equivalents and Short-Term Investments

Cash and cash equivalents consist of cash and highly liquid investments with contractual maturities of three months or less from the original purchase date.

Short-term investments consist of securities with contractual maturities of greater than three months from the original purchase date. Securities with contractual maturities greater than one year are classified as short-term investments on the condensed consolidated balance sheets, as we have the ability, if necessary, to liquidate these securities to meet our liquidity needs in the next 12 months. We have classified our short-term investments as available-for-sale securities in the accompanying condensed consolidated financial statements. Available-for-sale securities are stated at fair market value, with net changes in unrealized gains and losses reported in other comprehensive (loss) income and realized gains and losses included in other expense, net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income within other expense, net.

Our bank and investment accounts have been placed under a control agreement in accordance with our working capital facility agreement (see Note 8 - Long-Term Debt and Convertible Notes).

Concentration of Credit Risk

Cash, cash equivalents and short-term investments are financial instruments that potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits may be in excess of insured limits. We have not experienced any losses in such accounts and believe we are not exposed to significant risk with respect to our cash, cash equivalents and short-term investments, however, any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations and cash flows.

We may also invest our excess cash in money market funds, U.S. government and agencies, corporate debt securities and commercial paper. We have established guidelines relative to our diversification of our cash investments and their maturities in an effort to maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.

ZYNRELEF, APONVIE, CINVANTI and SUSTOL are distributed in the U.S. through a limited number of specialty distributors and full line wholesalers (collectively, "Customers") that resell to healthcare providers and hospitals, the end users of our Products.

The following table includes the percentage of net product sales and accounts receivable balances for our three major Customers, each of which comprised 10% or more of our product sales:


	Net Product Sales						Accounts Receivable
	Three Months Ended September 30, 2025			Nine Months Ended September 30, 2025			As of September 30, 2025
Customer A		38.8	%		42.2	%		40.6	%
Customer B		33.6	%		33.5	%		33.4	%
Customer C		25.8	%		22.8	%		25.5	%
Total		98.2	%		98.5	%		99.5	%

Accounts Receivable, Net

Accounts receivable are recorded at the invoice amount, net of an allowance for credit losses. The allowance for credit losses reflects accounts receivable balances that are believed to be uncollectible. In estimating the allowance for credit losses, we consider (1) our historical experience with collections and write-offs; (2) the credit quality of our Customers and any recent or anticipated changes thereto; (3) the outstanding balances and past due amounts from our Customers; and (4) reasonable and supportable forecast of economic conditions expected to exist throughout the contractual term of the receivable. As of September 30, 2025, and December 31, 2024, we do not have an allowance for credit losses.

Inventory, Net

Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out, or FIFO, basis. We periodically analyze our inventory levels and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory quantities that are in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less

favorable than projected by management, additional write-downs of inventory may be required, which would be recorded as cost of product sales.

Property and Equipment, Net

Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (generally 5 years). Leasehold improvements are stated at cost and amortized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. During the three and nine months ended September 30, 2025, we incurred a loss on the write-off of property and equipment of $0.3 million and $0.5 million, respectively, which was recorded to operating expense. During the three and nine months ended September 30, 2024 we incurred a loss on the write-off of property and equipment of $0.8 million and $4.3 million, respectively. Of the $4.3 million for the nine months ended September 30, 2024, $2.5 million was recorded to other expense, net and the remaining loss was recorded to operating expense.

Leases

We determine if an arrangement is a lease or contains lease components at inception. Operating leases with an initial term greater than 12 months are recorded as lease liabilities with corresponding right-of-use ("ROU") lease assets on the condensed consolidated balance sheets. ROU lease assets represent our right to use the underlying assets over the lease term, and lease liabilities represent the present value of our obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The ROU lease assets equal the lease liabilities, less unamortized lease incentives, unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease. The lease term includes any option to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. We have elected the practical expedient to not separate lease and non-lease components.

Revenue Recognition

Revenue is recognized in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("Topic 606"). Topic 606 is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

Product Sales

Our Products are distributed in the U.S. through a limited number of Customers that resell to healthcare providers and hospitals, the end users of our Products.

Revenue is recognized in an amount that reflects the consideration we expect to receive in exchange for our Products. To determine revenue recognition for contracts with Customers within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a Customer; (ii) identify the performance obligations of the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) we satisfy the performance obligations. We recognize revenue from Product sales when there is a transfer of control of the Product to our Customers. We typically determine transfer of control based on when the Product is delivered, and title passes to our Customers.

Product Sales Allowances

We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. Such variable consideration includes estimates that take into consideration the terms of our agreements with Customers, historical product returns, rebates or discounts taken, the shelf life of the product and specific known market events, such as competitive pricing and new product introductions. If actual future results vary from our estimates, we may need to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustment. Our product sales allowances include:

•

Product Returns—We allow the majority of our Customers to return product for credit beginning three months prior to the product expiration date and up to 12 months after the product expiration date. As such, there may be a significant period of time between the time the product is shipped and the time the credit is issued on returned product.

•

Distributor Fees—We pay distribution service fees to our Customers based on a contractually fixed percentage of the wholesale acquisition costs and fees for data. These fees are paid no later than two months after the quarter in which product was shipped.

•

Group Purchasing Organization ("GPO") Discounts and Rebates—We offer cash discounts to GPO members. These discounts are taken when the GPO members purchase product from our Customers, who then charge back to us the discount amount. Additionally, we offer volume and contract-tier rebates to GPO members. Rebates are based on actual purchase levels during the quarterly rebate purchase period.

•

GPO Administrative Fees—We pay administrative fees to GPOs for services and access to data. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the GPO's members.

•

Medicaid Rebates—We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state's guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within six months after the quarter in which the product was sold.

•

Prompt Pay Discounts—We may provide discounts on product sales to our Customers for prompt payment based on contractual terms.

We believe our estimated allowance for product returns and GPO discounts requires a high degree of judgment and is subject to change based on our experience and certain quantitative and qualitative factors. We believe our estimated allowances for distributor fees, GPO rebates and administrative fees, Medicaid rebates and prompt pay discounts do not require a high degree of judgment because the amounts are settled within a relatively short period of time.

Our product sales allowances and related accruals are evaluated each reporting period and adjusted when trends or significant events indicate that a change in estimate is appropriate. Changes in product sales allowance estimates could materially affect our results of operations and financial position.

The following table provides disaggregated net product sales (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
CINVANTI net product sales	$	23,955	$	22,662	$	73,841	$	73,205
SUSTOL net product sales		1,911		2,763		7,175		10,623
ZYNRELEF net product sales		9,313		6,245		25,542		17,089
APONVIE net product sales		3,034		1,140		7,758		2,587
Total net product sales	$	38,213	$	32,810	$	114,316	$	103,504

The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands):


	Product Returns			Distributor Fees			Discounts, Rebates and Administrative Fees			Total
Balance at December 31, 2024	$	3,791		$	5,883		$	27,745		$	37,419
Provision		1,544			25,949			170,019			197,512
Payments/credits		(842	)		(25,264	)		(167,462	)		(193,568	)
Balance at September 30, 2025	$	4,493		$	6,568		$	30,302		$	41,363

Comprehensive Loss

Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net changes in unrealized gains and losses on available-for-sale securities are included in other comprehensive loss and represent the difference between our net loss and comprehensive loss for all periods presented.

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, including pre-funded warrants to purchase shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, restricted stock units, warrants and shares of common stock underlying convertible notes are considered to be common stock equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive.

Because we have incurred a net loss for the three and nine months ended September 30, 2025 and 2024, the following common stock equivalents were not included in the computation of net loss per share because their effect would be anti-dilutive (in thousands):


	As of September 30,
	2025		2024
Stock options outstanding		28,888		26,156
Restricted stock units outstanding		4,014		1,547
Warrants outstanding		298		298
Shares of common stock underlying convertible notes outstanding		19,444		9,819
Series A Preferred Stock convertible to common shares		5,241		—

Segment Reporting

Management, upon consideration of the organizational structure of the business and information reviewed by the Company's Chief Executive Officer, who is also the Company's chief operating decision maker ("CODM"), has concluded that we have one reportable segment. All revenues for the three and nine months ended September 30, 2025 and 2024 were generated from customers in the U.S. The CODM allocates resources and evaluates the performance of the reportable segment, which is the consolidated entity, primarily based on net loss as reported on the consolidated statements of operations and comprehensive loss. The significant expenses reviewed by the CODM are cost of product sales, research and development expenses, general and administrative expenses, and sales and marketing expenses as reported on the consolidated statements of operations and comprehensive loss. The Company's operating segments do not record intercompany revenue nor allocate any expenses. The CODM does not evaluate operating segments using discrete asset information.

Recently Adopted Accounting Standards

In November 2024, the FASB issued ASU No. 2024-04, Induced Conversions of Convertible Debt Instruments ("ASU 2024-04"), to improve the consistency in application of the induced conversion guidance in Subtopic 470-20, Debt - Debt with Conversions and Other Options. We early adopted the provisions of ASU 2024-04 in the three months ended September 30, 2025 and concluded that the settlement of the 2026 Convertible Notes did not represent an induced conversion. Refer to Note 8 - Long-Term Debt and Convertible Notes for evaluation of the accounting of the transaction.

Recently Issued Accounting Standards Not Yet Adopted

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. We have evaluated recently issued accounting pronouncements and do not believe any will have a material impact on our condensed consolidated financial statements or related financial statement disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), to enhance income tax reporting disclosures and require disclosure of specific categories in the tabular rate reconciliation. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, on a prospective basis. Early adoption and retrospective application are permitted. We are currently evaluating the impact on our disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"), which requires disaggregated disclosures of certain categories of expenses that are included in the face of the financial statements. This standard is effective for fiscal years beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. We are currently evaluating the impact on our disclosures.

4. Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:

•

Level 1—Observable inputs such as quoted prices in active markets for identical assets or liabilities.

•

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

We measure cash, cash equivalents and short-term investments at fair value on a recurring basis. The fair values of such assets were as follows (in thousands):


			Fair Value Measurements at Reporting Date Using
	Balance at September 30, 2025		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and money market funds	$	36,397	$	36,397	$	—	$	—
U.S. Treasury bills and government agency obligations		6,732		6,732		—		—
U.S. corporate debt securities		5,018		—		5,018		—
Foreign commercial paper		6,551		—		6,551		—
U.S. commercial paper		789		—		789		—
Total	$	55,487	$	43,129	$	12,358	$	—


			Fair Value Measurements at Reporting Date Using
	Balance at December 31, 2024		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and money market funds	$	23,860	$	23,860	$	—	$	—
U.S. Treasury bills and government agency obligations		14,868		14,868		—		—
U.S. corporate debt securities		13,644		—		13,644		—
Foreign corporate debt securities		5,913		—		5,913		—
Foreign commercial paper		998		—		998		—
Total	$	59,283	$	38,728	$	20,555	$	—

We have not transferred any investment securities between the three levels of the fair value hierarchy for the three and nine months ended September 30, 2025 or 2024.

As of September 30, 2025, cash equivalents included $16.9 million of available-for-sale securities with contractual maturities of three months or less and short-term investments included $5.3 million of available-for-sale securities with contractual maturities of three months to one year. As of December 31, 2024, cash equivalents included $1.9 million of available-for-sale securities with contractual maturities of three months or less and short-term investments included $9.0 million of available-for-sale securities with contractual maturities of three months to one year. The money market funds as of September 30, 2025 and December 31, 2024 are included in cash and cash equivalents on the condensed consolidated balance sheets.

A company may elect to use fair value to measure accounts receivable, available-for-sale securities, accounts payable, guarantees and issued debt, among others. If the use of fair value is elected, any upfront costs and fees related to the item such as debt issuance costs must be recognized in earnings and cannot be deferred. The fair value election is irrevocable and generally made on an instrument-by-instrument basis, even if a company has similar instruments that it elects not to measure based on fair value. Unrealized gains and losses on existing items for which fair value has been elected are reported as a cumulative adjustment to beginning retained earnings and any changes in fair value are recognized in earnings. We have elected to not apply the fair value option to our financial assets and liabilities.

Financial instruments, including cash, cash equivalents, receivables, inventory, prepaid expenses, other current assets, accounts payable and accrued expenses are carried at cost, which is considered to be representative of their respective fair values because of the short-term maturity of these instruments. Short-term available-for-sale investments are carried at fair value. Our notes payable and convertible notes payable outstanding at September 30, 2025 and December 31, 2024 do not have a readily available ascertainable market value; however, their carrying value, which is measured at carrying value less unamortized debt issuance costs and debt discounts, is considered to approximate their fair value.

5. Short-Term Investments

The following is a summary of our short-term investments (in thousands):


	September 30, 2025
			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
	Cost		Gains		Losses		Fair Value
U.S. Treasury bills and government agency obligations	$	3,742	$	—	$	—	$	3,742
U.S. corporate debt securities		4,519		—		—		4,519
U.S. commercial paper		789		—		—		789
Foreign commercial paper		3,369		—		—		3,369
Total	$	12,419	$	—	$	—	$	12,419


	December 31, 2024
			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
	Cost		Gains		Losses		Fair Value
U.S. Treasury bills and government agency obligations	$	14,860	$	8	$	—	$	14,868
U.S. corporate debt securities		11,699		3		—		11,702
Foreign corporate debt securities		5,911		2		—		5,913
Foreign commercial paper		998		—		—		998
Total	$	33,468	$	13	$	—	$	33,481

The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. We regularly monitor and evaluate the realizable value of our marketable securities. We did not recognize any impairment losses during the three and nine months ended September 30, 2025 and 2024.

Unrealized gains and losses associated with our investments are reported in accumulated other comprehensive loss. Realized gains and losses associated with our investments, if any, are reported in the statements of operations and comprehensive loss. We did not recognize any realized gains or losses during the three and nine months ended September 30, 2025 and 2024.

6. Inventory

Inventory consists of the following (in thousands):


	September 30, 2025		December 31, 2024
Raw materials	$	32,785	$	19,733
Work in process		26,343		27,190
Finished goods		10,897		6,237
Total inventory	$	70,025	$	53,160


	September 30, 2025		December 31, 2024
CINVANTI	$	30,434	$	36,484
SUSTOL		1,477		3,206
APONVIE		5,427		1,626
ZYNRELEF		32,687		11,844
Total inventory	$	70,025	$	53,160

For the three and nine months ended September 30, 2025, cost of product sales included charges of $2.2 million and $2.7 million, respectively relating to reserves and write-offs of inventory. For the three and nine months ended September 30, 2024, cost of product sales included charges of $0.8 million and $2.4 million, respectively, relating to reserves and write-offs of inventory.

7. Leases

As of September 30, 2025, we had an operating lease for 52,148 square feet of laboratory and office space in San Diego, California, with a lease term that expires on December 31, 2025. In October 2021, we entered into a sublease agreement to sublet 23,873 square feet of laboratory and office space in San Diego, California. The space was delivered to the subtenant in March 2022. As a result of the sublease agreement, our one five-year option to renew this lease on expiration applies only with respect to our remaining 28,275 square feet of laboratory and office space. In August 2025, we entered into a lease agreement for 16,837 square feet of office space in Cary, North Carolina, with the lease term expected to commence no later than May 25, 2026 (“lease commencement date”) and expire 111 months from the lease commencement date, with the option to extend for one additional period of 84 months upon written notice. As the lease commencement date has not yet occurred, no right-of-use asset or lease liability has been recognized in the accompanying condensed consolidated financial statements. We provided the landlord with a letter of credit for $0.2 million, which is included within cash and cash equivalents in the condensed consolidate balance sheet.

During the three and nine months ended September 30, 2025, we recognized $0.8 million and $2.3 million of operating lease expense, respectively. During the three and nine months ended September 30, 2025, we paid $0.8 million and $2.4 million, respectively, for our operating leases.

During the three and nine months ended September 30, 2024, we recognized $0.7 million and $2.2 million of operating lease expense, respectively. During the three and nine months ended September 30, 2024, we paid $0.8 million and $2.4 million, respectively, for our operating leases.

Annual future minimum lease payments as of September 30, 2025 are as follows (in thousands):


2025	$	785
Less: discount		(5	)
Total lease liabilities	$	780

8. Long-Term Debt and Convertible Notes

Working Capital Facility Agreement

On August 9, 2023, we entered into a working capital facility agreement (the "Initial Working Capital Facility Agreement") with Hercules Capital, Inc., as administrative agent, collateral agent, and lender (the “Lender”). The Initial Working Capital Facility Agreement provided for an aggregate principal amount of up to $50.0 million with tranched availability as follows: (i) $25.0 million at closing on August 9, 2023 ("tranche 1A"), (ii) $5.0 million available through December 15, 2024 ("tranche 1B") and (iii) $20.0 million available from the earlier of: (a) the full draw of tranche 1B and (b) the expiration of tranche 1B, and available through December 15, 2025 ("tranche 1C"), and in the case of tranches 1B and 1C, subject to certain customary conditions to draw down.

The Initial Working Capital Facility Agreement had a term of four years, with a springing maturity date that was 91 days prior to the stated maturity of our 2026 Convertible Notes (as defined below), if still outstanding at such time. The loans thereunder did not have any scheduled amortization payments and accrued interest at a floating rate equal to 9.95% per annum, payable in cash on a monthly basis and upon maturity or payoff. In addition, any loans under the Initial Working Capital Facility Agreement also accrued paid-in-kind interest at a fixed rate of 1.5% per annum which was due upon maturity or payoff.

In addition, in connection with the tranche 1A funding, we issued warrants to the Lender to purchase up to 297,619 shares of our common stock at an exercise price of $1.68 per share (the "Lender Warrants"). The Lender Warrants are equal to 2.00% of the principal amount of the tranche 1A loans funded by the Lender (the "Warrant Coverage"). The Initial Working Capital Facility Agreement also required that we issue additional warrants to the Lender at the time of each draw down of tranches 1B and 1C with the same Warrant Coverage. Each Lender Warrant is exercisable for seven years from the date of issuance. The Lender Warrant issued in conjunction with the tranche 1A funding remains outstanding at September 30, 2025.

On February 13, 2025, we entered into an amendment to the Initial Working Capital Facility Agreement (the “First Amendment to the Working Capital Facility Agreement”) to extend the maturity date to the earlier of (a) September 1, 2027 and (b) to the extent that any of the 2026 Convertible Notes remain outstanding on such date, (i) May 12, 2026 or (ii) in the event that the maturity date of any 2026 Convertible Notes is extended, prior to May 12, 2026, to August 11, 2026, or later, the date that is 91 days prior to the maturity date of such further extended 2026 Convertible Notes.

On August 8, 2025, we entered into an amendment to the Initial Working Capital Facility Agreement, as amended by the First Amendment to the Working Capital Facility Agreement (the “Second Amendment to the Working Capital Facility Agreement”). The Second Amendment to the Working Capital Facility Agreement (i) provides for an aggregate principal amount of up to $150.0 million plus the accrued and unpaid paid-in-kind interest on the existing debt under the Initial Working Capital Facility Agreement at closing on August 12, 2025, (ii) extends the maturity date under the First Amendment to the Working Capital Facility Agreement to September 1, 2030, (iii) adjusts the interest rate to Prime, with a 7.5% floor, plus 1.95%, (iv) adjusts the paid-in-kind interest rate to 1.0% per annum, which is due upon maturity or payoff, (iv) provides for payment of a 1.0% upfront facility charge and an end of term charge of up to 6.25% of principal drawn. The loans under the Second Amendment to the Working Capital Facility Agreement do not have any scheduled amortization payments. The approximately $150.0 million aggregate principal has tranched availability as follows: (i) $110.0 million plus capitalized paid-in-kind interest of approximately $0.8 million on August 12, 2025 (“tranche 1”), (ii) $20.0 million available through December 15, 2026 (“tranche 2”) and (iii) $20.0 million available from the earlier of: (a) the full draw of tranche 2 and (b) September 30, 2027 (“tranche 3”), and in the case of tranches 2 and 3, subject to certain customary conditions to draw down.

The Second Amendment to the Working Capital Facility Agreement contains a minimum cash covenant, a minimum revenue covenant and a minimum EBITDA covenant. The Second Amendment to the Working Capital Facility Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions. We were in compliance with all covenants of the Second Amendment to the Working Capital Facility Agreement as of September 30, 2025. The Initial Working Capital Facility Agreement, together with the First Amendment to the Working Capital Facility Agreement and the Second Amendment to the Working Capital Facility Agreement are referred to as the “Working Capital Facility Agreement”.

The Second Amendment to the Working Capital Facility Agreement was accounted for in accordance with ASC Topic 470, Debt. Amendments are assessed by management to determine appropriate treatment as troubled debt restructurings, extinguishments

or modifications. The Second Amendment to the Working Capital Facility Agreement qualifies as a debt extinguishment and issuance of a new debt instrument. We recorded a loss on extinguishment during the quarter ended September 30, 2025, of $5.5 million, equal to the carrying value of the Second Amendment to the Working Capital Facility Agreement less the carrying value of the First Working Capital Facility Agreement on August 12, 2025 of $0.3 million, the facility charge of $1.1 million paid to the lenders, the remaining Initial Working Capital Facility Agreement end of term fee of $0.2 million and the present value of Second Amendment to the Working Capital Facility Agreement end of term fee of $3.9 million. The Initial Working Capital Facility Agreement end of term fee is payable on September 1, 2027. The remaining Second Amendment to the Working Capital Facility Agreement end of term fee will be accreted to interest expense over the term of the agreement using the effective interest rate method.

The tranche 1 funding under the Second Amendment to the Working Capital Facility Agreement of $110.0 million plus the accrued and unpaid paid-in-kind interest of $0.7 million from the Initial Working Capital Facility Agreement are accounted for as debt and was recorded as a liability on the condensed consolidated balance sheets. In addition, the additional borrowings available under the Second Amendment to the Working Capital Facility Agreement are accounted for as a single freestanding financial instrument that are not assets or obligations of ours and will be accounted for when and if we borrow additional tranches in the future.

In connection with the Second Amendment to the Working Capital Facility Agreement, we incurred debt issuance costs of $3.5 million, which was recorded as a debt discount. The debt discount is being amortized into interest expense using the effective interest rate method over the term of the Second Amendment to the Working Capital Facility Agreement. The effective interest rate as of September 30, 2025 is 11.6%.

For the three and nine months ended September 30, 2025, interest expense related to the Working Capital Facility Agreement was $2.2 million and $4.0 million, respectively, which included $1.7 million and $3.0 million, respectively, related to the stated interest rate, $0.2 million and $0.4 million, respectively, related to paid-in-kind interest, and $0.2 million and $0.6 million, respectively, related to the amortization of the debt discounts and accretion of the end of term fee.

For the three and nine months ended September 30, 2024, interest expense related to the Working Capital Facility Agreement was $0.9 million and $2.7 million, respectively, which included $0.6 million and $1.9 million, respectively, related to the stated interest rate, $0.1 million and $0.3 million, respectively, related to paid-in-kind interest, and $0.2 million and $0.5 million, respectively, related to the amortization of the debt discounts.

As of September 30, 2025, the carrying value of the Working Capital Facility Agreement was $107.5 million, which is comprised of the $110.8 million principal amount outstanding, $0.1 million of accumulated paid-in-kind interest, less debt discounts of $3.4 million. The end of term fee accreted as of September 30, 2025, of $4.7 million is recorded in other non-current liabilities on the condensed consolidated balance sheets.

2026 Senior Unsecured Convertible Notes

In May 2021, we entered into a note purchase agreement with funds affiliated with Baker Bros. Advisors LP for a private placement of $150.0 million aggregate principal amount of senior unsecured convertible notes due 2026 (the “2026 Convertible Notes”). We received a total of $149.0 million, net of issuance costs, from the issuance of the 2026 Convertible Notes.

The 2026 Convertible Notes bear interest at a rate of 1.5% per annum, payable in cash semi-annually in arrears on June 15 and December 15 of each year with a maturity date of May 26, 2026, unless earlier converted, redeemed or repurchased.

The 2026 Convertible Notes were accounted for in accordance with ASC Subtopic 470-20, Debt with Conversion and Other Options (“ASC 470-20”), and ASC Subtopic 815-40, Contracts in Entity's Own Equity (“ASC 815-40”). Under ASC 815-40, to qualify for equity classification (or non-bifurcation, if embedded), the instrument (or embedded feature) must be both (1) indexed to the issuer's stock and (2) meet the requirements of the equity classification guidance. Based upon our analysis, it was determined that the 2026 Convertible Notes do contain embedded features indexed to our common stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and, also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20, the proceeds received from the issuance of the 2026 Convertible Notes were recorded as a liability on the condensed consolidated balance sheets.

We incurred issuance costs related to the 2026 Convertible Notes of $1.0 million, which we recorded as debt issuance costs and were included as a reduction to the 2026 Convertible Notes on the condensed consolidated balance sheets. The debt issuance costs are

being amortized to interest expense using the effective interest rate method over the term of the 2026 Convertible Notes, resulting in an effective interest rate of 1.6%.

On August 8, 2025, we entered into an exchange agreement pursuant to which $150.0 million aggregate principal amount of the 2026 Convertible Notes outstanding were exchanged for (i) 16,666,666 shares of common stock for an aggregate principal amount of $25.0 million of the 2026 Convertible Notes and (ii) the remaining $125.0 million plus accrued and unpaid interest under the 2026 Convertible Notes paid in cash, and which closed on August 12, 2025. As of September 30, 2025, no 2026 Convertible Notes remain outstanding.

The exchange agreement was accounted for in accordance with ASC 470-20, after the adoption of ASU 2024-04, whereby we concluded that the exchange did not qualify as an induced conversion. Thus, we accounted for the exchange as a debt extinguishment. We recorded a loss on extinguishment during the quarter ended September 30, 2025 of $5.8 million, which was equal to the carrying value of the 2026 Convertible Notes less the fair value of the consideration offered in the exchange. The fair value of the consideration offered in the exchange was determined to be $125.0 million for the cash consideration and $

For the quarterly period ended September 30, 2025

For the transition period from _______ to _______

HERON THERAPEUTICS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

Condensed Consolidated Statements of Stockholders' Equity (Deficit)

Condensed Consolidated Statements of Cash Flows

For the transition period from _ to _

HERON THERAPEUTICS, INC. /DE/ 10-Q